Progress and challenges in the vaccine-based treatment of head and neck cancers

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Venuti, Aldo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PANITUMUMAB; TUMOR ANTIGEN; CANCER VACCINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; HEAD AND NECK CANCER; HLA SYSTEM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; WART VIRUS; HEAD AND NECK TUMOR; REVIEW;

CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 67650757467     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-69     Document Type: Article

References (98)

1. Coley's toxins, tumour necrosis factor and cancer research: a historical perspective. B Wiemann CO Starnes, Pharmacol Ther 1994 64 529 64 7724661
2. Head and neck cancer antigens recognized by the humoral immune system. M Monji S Senju T Nakatsura K Yamada M Sawatsubashi A Inokuchi Y Nishimura, Biochem Biophys Res Commun 2002 294 734 741 12056832 (Pubitemid 34694074)
3. Immunotherapy for head and neck cancer. AA Wu KJ Niparko SI Pai, J Biomed Sci 2008 15 275 89 Epub 2008 Apr 5. Review. 18392689
4. Head and neck cancer immunotherapy: clinical evaluation. MS Leibowitz JV Nayak RL Ferris, Curr Oncol Rep 2008 10 162 9 Review. 18377830
5. Anti-tumour vaccines in head and neck cancer: targeting immune responses to the tumour. TL Whiteside, Curr Cancer Drug Targets 2007 7 633 42 Review. 18045068
6. Human papillomavirus therapeutic vaccines in head and neck tumours. G Badaracco A Venuti, Expert Rev Anticancer Ther 2007 7 753 66 Review. 17492938
7. Presence of HPV in head and neck tumours: high prevalence in tonsillar localization. A Venuti G Badaracco C Rizzo B Mafera S Rahimi M Vigili, J Exp Clin Cancer Res 2004 23 561 6 15743024
8. How will HPV vaccines affect cervical cancer? R Roden TC Wu, Nat Rev Cancer 2006 6 753 76 16990853
9. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. M Meissner TE Reichert M Kunkel W Gooding TL Whiteside S Ferrone B Seliger, Clin Cancer Res 2005 11 2552 2560 15814633 (Pubitemid 40569453)
10. Tumour sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumour model for HPV-transformed tumours. ME Dominiecki GL Beatty ZK Pan P Neeson Y Paterson, Cancer Immunol Immunother 2005 54 477 488 15750832 (Pubitemid 40543687)
11. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. A Lopez-Albaitero JV Nayak T Ogino A Machandia W Gooding AB DeLeo S Ferrone RL Ferris, J Immunol 2006 176 3402 3409 16517708 (Pubitemid 43363987)
12. A uniquesubset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediatessuppression in the tumour microenvironment. L Strauss C Bergmann M Szczepanski W Gooding JT Johnson TL Whiteside, Clin Cancer Res 2007 13 4345 4354 17671115 (Pubitemid 47219698)
13. Rapid tolerization of virus-activated tumour-specific CD8+ T cells in prostate tumours of TRAMP mice. A Bai E Higham HN Eisen KD Wittrup J Chen, Proc Natl Acad Sci USA 2008 105 13003 8 Epub 2008 Aug 22. 18723683
14. Tumour-infiltrating lymphocytes: Their phenotype, functions and clinical use. TL Whiteside G Parmiani, Cancer Immunol Immunother 1994 39 15 21 8044822 (Pubitemid 24216607)
15. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients withmetastatic melanoma. GQ Phan JC Yang RM Sherry P Hwu SL Topalian DJ Schwartzentruber NP Restifo LR Haworth CA Seipp LJ Freezer KE Morton SA Mavroukakis PH Duray SM Steinberg JP Allison TA Davis SA Rosenberg, Proc Natl Acad Sci USA 2003 100 8372 8377 12826605 (Pubitemid 36842552)
16. Antitumour activity in melanoma and anti-self responses in phase 1 trial with anti-cytotoxis T lymphocyte associated antigen 4 monoclonal antibody. A Ribas L Camacho G Lopez-Berestein, J Clin Oncol 2005 23 8968 16204013
17. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumour immunity. AD Cohen A Diab MA Perales JD Wolchok G Rizzuto T Merghoub D Huggins C Liu MJ Turk NP Restifo S Sakaguchi AN Houghton, Cancer Res 2006 66 4904 12 16651447
18. Treatment of advanced tumours with agonistic anti-GITR mAb and its effects on tumour-infiltrating Foxp3+CD25+CD4+ regulatory T cells. K Ko S Yamazaki K Nakamura T Nishioka K Hirota T Yamaguchi J Shimizu T Nomura T Chiba S Sakaguchi, J Exp Med 2005 202 885 91 16186187
19. Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. S Tuyaerts S Van Meirvenne A Bonehill C Heirman J Corthals H Waldmann K Breckpot K Thielemans JL Aerts, J Leukoc Biol 2007 82 93 105 17449724 (Pubitemid 47026420)
20. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumour necrosis factor receptor-ligand (GITRL). S Hanabuchi N Watanabe YH Wang T Ito J Shaw W Cao FX Qin YJ Liu, Blood 2006 107 3617 3623 16397134
21. Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. E Marshall, Science 2006 311 1688 9 16556805
22. Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. JW Kim RL Ferris TL Whiteside, Clin Cancer Res 2005 11 7901 7910 16278415 (Pubitemid 41611637)
23. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. TT Tomson RB Roden TC Wu, Curr Opin Investig Drugs 2004 5 1247 1261 15648945 (Pubitemid 40074965)
24. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. MH Tao R Levy, Nature 1993 362 755 758 8469286
25. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. TT Chen MH Tao R Levy, J Immunol 1994 153 4775 4787 7525715 (Pubitemid 24346873)
26. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. RS Chu OS Targoni AM Krieg PV Lehmann CV Harding, J Exp Med 1997 186 1623 1631 9362523 (Pubitemid 27506276)
27. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. M Roman E Martin-Orozco JS Goodman MD Nguyen Y Sato A Ronaghy RS Kornbluth DD Richman DA Carson E Raz, Nat Med 1997 3 849 854 9256274 (Pubitemid 27353443)
28. Anti-cancer activity of plant-produced HPV16 E7 vaccine. S Massa R Franconi R Brandi A Muller V Mett V Yusibov A Venuti, Vaccine 2007 25 3018 3021 17280752 (Pubitemid 46505044)
29. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. A Venuti S Massa V Mett L Dalla Vedova F Paolini V Franconi V Yusibov, Vaccine 2009 19200826
30. Targeting p53 as a general tumour antigen. M Theobald J Biggs D Dittmer AJ Levine LA Sherman, Proc Natl Acad Sci USA 1995 92 11993 11997 8618830 (Pubitemid 26013997)
31. p53-based immunotherapy of cancer. AB DeLeo, Crit Rev Immunol 1998 18 29 35 9419445 (Pubitemid 27528179)
32. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. K Chikamatsu K Nakano WJ Storkus E Appella MT Lotze TL Whiteside AB DeLeo, Clin Cancer Res 1999 5 1281 1288 10389910 (Pubitemid 29282930)
33. DNA vaccines: immunology, application, and optimization. S Gurunathan DM Klinman RA Seder, Annu Rev Immunol 2000 18 927 974 10837079 (Pubitemid 30365401)
34. Antigen presentation and T cell stimulation by dendritic cells. P Guermonprez J Valladeau L Zitvogel C Thery S Amigorena, Annu Rev Immunol 2002 20 621 667 11861614 (Pubitemid 34293436)
35. A Toll-like receptor recognizes bacterial DNA. H Hemmi O Takeuchi T Kawai T Kaisho S Sato H Sanjo M Matsumoto K Hoshino H Wagner K Takeda S Akira, Nature 2000 408 740 745 11130078 (Pubitemid 32015992)
36. HPV DNA vaccines. M Moniz M Ling CF Hung TC Wu, Front Biosci 2003 8 55 68 Review.
37. Antitumour activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. S Massa P Simeone A Muller E Benvenuto A Venuti R Franconi, Hum Gene Ther 2008 19 354 64 18439124
38. ombination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. BW O'Malley Jr D Li SJ McQuone R Ralston, Laryngoscope 2005 115 C391 404 (Pubitemid 40327983)
39. Therapeutic human papillomavirus vaccines. M Ling TC Wu, Cervical cancer: from etiology to prevention Boston: Kluwer Academic Publishers, Rohan TE, Shah KV, 2004 345 376
40. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumour in a transgenic mouse model of cancer. NC Souders DA Sewell ZK Pan SF Hussain A Rodriguez A Wallecha Y Paterson, Cancer Immun 2007 7 2 12 17279610
41. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. LK Borysiewicz A Fiander M Nimako S Man GW Wilkinson D Westmoreland AS Evans M Adams SN Stacey ME Boursnell E Rutherford JK Hickling SC Inglis, Lancet 1996 347 1523 1527 8684105 (Pubitemid 26162644)
42. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. M Adams L Borysiewicz A Fiander S Man B Jasani H Navabi C Lipetz AS Evans M Mason, Vaccine 2001 19 2549 2556 11257391 (Pubitemid 32234271)
43. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. AM Kaufmann PL Stern EM Rankin H Sommer V Nuessler A Schneider M Adams TS Onon T Bauknecht U Wagner K Kroon J Hickling CM Boswell SN Stacey HC Kitchener J Gillard J Wanders JS Roberts H Zwierzina, Clin Cancer Res 2002 8 3676 3685 12473576 (Pubitemid 35424757)
44. mmunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. EJ Davidson CM Boswell P Sehr M Pawlita AE Tomlinson RJ McVey J Dobson JS Roberts J Hickling HC Kitchener PL Stern, Cancer Res. 2003 63 18 I6032 6041 (Pubitemid 37187507)
45. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. PJ Baldwin SH van der Burg CM Boswell R Offringa JK Hickling J Dobson JS Roberts JA Latimer RP Moseley N Coleman MA Stanley JC Sterling, Clin Cancer Res 2003 9 5205 5213 14614000 (Pubitemid 37413570)
46. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). EJ Davidson RL Faulkner P Sehr M Pawlita LJ Smyth DJ Burt AE Tomlinson J Hickling HC Kitchener PL Stern, Vaccine 2004 22 2722 2729 15246603 (Pubitemid 38900647)
47. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. CM Corona Gutierrez A Tinoco T Navarro ML Contreras RR Cortes P Calzado L Reyes R Posternak G Morosoli ML Verde R Rosales, Hum Gene Ther 2004 15 421 431 15144573 (Pubitemid 38639614)
48. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. E Garcia-Hernandez JL Gonzalez-Sanchez A Andrade-Manzano ML Contreras S Padilla CC Guzman R Jimenez L Reyes G Morosoli ML Verde R Rosales, Cancer Gene Ther 2006 13 592 597 16456551 (Pubitemid 43756247)
49. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. YCA Albarran A de la Garza BJ Cruz Quiroz E Vazquez Zea I Diaz Estrada E Mendez Fuentez M Lopez Contreras A Andrade-Manzano S Padilla AR Varela R Rosales, BioDrugs 2007 21 47 59 17263589 (Pubitemid 46232456)
50. HPV Vaccines in Plants: an appetising solution to Control Infection and Associated Cancers. R Franconi A Venuti, Papillomavirus research: from Natural History to Vaccines and Beyond Norfolk, U.K.: Caister Academic Press, Saveria Campo M, 2006 357 372
51. Monoclonal antibody manufacturing in transgenic plants myths and realities. EE Hood SL Woodard ME Horn, Curr Opin Biotechnol 2002 13 630 635 12482526 (Pubitemid 35448068)
52. Rapid production of specific vaccines for lymphoma by expression of the tumour-derived single-chain Fv epitopes in tobacco plants. AA McCormick MH Kumagai K Hanley TH Turpen I Hakim LK Grill D Tusè S Levy R Levy, Proc Natl Acad Sci USA 1999 96 703 708 9892697 (Pubitemid 29061272)
53. Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumour Ig. AA McCormick SJ Reinl TI Cameron F Vojdani M Fronefield R Levy D Tusè J Immunol Methods 2003 278 95 104 12957399 (Pubitemid 37287600)
54. Expression and assembly of a full-length monoclonal antibody in plants using a plant-virus vector. T Verch V Yusibov H Koprowski, J Immunol Methods 1998 220 69 75 9839927 (Pubitemid 28527068)
55. mmunization with a plant-produced colorectal cancer antigen. T Verch DC Hooper A Kiyatkin Z Steplewski H Koprowski, Cancer Immunol Immunother 2004 53 92 99 14566428 (Pubitemid 38161215)
56. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumour protection. R Franconi P Di Bonito F Dibello L Accardi A Muller A Cirilli P Simeone G Don A Venuti C Giorgi, Cancer Research 2002 62 3654 58 12097270
57. Strategies for antigen loading of dendritic cells to enhance the antitumour immune response. Y Son R Mailliard S Watkins M Lotze, Cancer Res 2002 62 1884 1889 11912169
58. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. W Weng D Czerwinski J Timmerman F Hsu R Levy, J Clin Oncol 2004 22 4717 4724 15483014
59. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. C Redfern T Guthrie A Bessudo JJ Densmore PR Holman N Janakiraman JP Leonard RL Levy RG Just MR Smith FP Rosenfelt PH Wiernik WD Carter DP Gold TJ Melink JC Gutheil JF Bender, J Clin Oncol 2006 24 3107 3112 16754937 (Pubitemid 46638948)
60. Dendritic cellbased tumour vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. A Ferrara M Nonn P Sehr C Schreckenberger M Pawlita M Durst A Schneider AM Kaufmann, J Cancer Res Clin Oncol 2003 129 521 530 12898233 (Pubitemid 37211193)
61. Considerations for the clinical development of cytokine gene-transduced tumour cell vaccines. EM Jaffee DM Pardoll, Methods 1997 12 143 153 9184378 (Pubitemid 27241370)
62. Costimulation of anti-tumour immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. L Chen S Ashe WA Brady I Hellstrom KE Hellstrom JA Ledbetter P McGowan PS Linsley, Cell 1992 71 1093 1102 1335364 (Pubitemid 23016545)
63. Tumour rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. SE Townsend JP Allison, Science 1993 259 368 370 7678351
64. Regression of a disseminated syngeneic solid tumour by systemic transfer of lymphoid cells expanded in interleukin 2. T Eberlein M Rosenstein S Rosenberg, J Exp Med 1982 156 385 397 6980254 (Pubitemid 12041402)
65. A new approach to the adoptive immunotherapy of cancer with tumourinfiltrating lymphocytes. S Rosenberg P Spiess R Lafreniere, Science 1986 233 1318 1321 3489291 (Pubitemid 16002234)
66. gp100/pmel 17 is a murine tumour rejection antigen: Induction of self reactive, tumouricidal T cells using high-affinity, altered peptide ligand. W Overwijk A Tsung K Irvine MR Parkhurst TJ Goletz K Tsung MW Carroll C Liu B Moss SA Rosenberg NP Restifo, J Exp Med 1998 188 277 286 9670040 (Pubitemid 28357756)
67. Passive immunotherapy of cancer in animals and man. S Rosenberg W Terry, Adv Cancer Res 1977 25 323 326003
68. Treatment of patients with metastatic melanoma with autologous tumour-infiltrating lymphocytes and interleukin 2. SA Rosenberg JR Yannelli JC Yang SL Topalian DJ Schwartzentruber JS Weber DR Parkinson CA Seipp JH Einhorn DE White, J Natl Cancer Inst 1994 86 1159 1166 8028037 (Pubitemid 24249302)
69. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. C Yee J Thompson P Roche DR Byrd PP Lee M Piepkorn K Kenyon MM Davis SR Riddell PD Greenberg, J Exp Med 2000 192 1637 1644 11104805
70. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. M Dudley J Wunderlich M Nishimura D Yu JC Yang SL Topalian DJ Schwartzentruber P Hwu FM Marincola R Sherry SF Leitman SA Rosenberg, J Immunother 2001 24 363 373 11565838 (Pubitemid 32825868)
71. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous antigen-specific T lymphocytes in patients with metastatic melanoma. M Dudley J Wunderlich JC Yang P Hwu DJ Schwartzentruber SL Topalian RM Sherry FM Marincola SF Leitman CA Seipp L Rogers-Freezer KE Morton A Nahvi SA Mavroukakis DE White SA Rosenberg, J Immunother 2002 25 243 251 12000866 (Pubitemid 34533314)
72. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumour depends on elimination of tumour-induced suppressor T cells. R North, J Exp Med 1982 155 1063 1074 6460831
73. Cancer regression and autoimmunity in patients after clonal repopulation with antitumour lymphocytes. ME Dudley JR Wunderlich PF Robbins JC Yang P Hwu DJ Schwartzentruber SL Topalian R Sherry NP Restifo AM Hubicki MR Robinson M Raffeld P Duray CA Seipp L Rogers-Freezer KE Morton SA Mavroukakis DE White SA Rosenberg, Science 2002 298 850 854 12242449 (Pubitemid 35231542)
74. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. P Robbins M Dudley J Wunderlich M El-Gamil YF Li J Zhou J Huang DJ Powell Jr SA Rosenberg, J Immunol 2004 173 7125 7130 15585832 (Pubitemid 39628146)
75. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. M Dudley J Wunderlich J Yang RM Sherry SL Topalian NP Restifo RE Royal U Kammula DE White SA Mavroukakis LJ Rogers GJ Gracia SA Jones DP Mangiameli MM Pelletier J Gea-Banacloche MR Robinson DM Berman AC Filie A Abati SA Rosenberg, J Clin Oncol 2005 23 2346 2357 15800326 (Pubitemid 46218728)
76. Comparing antibody and smallmolecule therapies for cancer. K Imai A Takaoka, Nat Rev Cancer 2006 6 714 727 16929325 (Pubitemid 44286003)
77. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Y Kawaguchi K Kono K Mimura H Sugai H Akaike H Fujii, Int J Cancer 2007 120 781 787 17096332 (Pubitemid 46175397)
78. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. H Modjtahedi DK Moscatello G Box M Green C Shotton DJ Lamb LJ Reynolds AJ Wong C Dean H Thomas S Eccles, Int J Cancer 2003 105 273 280 12673691 (Pubitemid 36505333)
79. Molecular therapy of head and neck cancer. H Modjtahedi, Cancer Metastasis Rev 2005 24 129 146 15785877 (Pubitemid 40576068)
80. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. JA Bonner PM Harari J Giralt N Azarnia DM Shin RB Cohen CU Jones R Sur D Raben J Jassem R Ove MS Kies J Baselga H Youssoufian N Amellal EK Rowinsky KK Ang, N Engl J Med 2006 354 567 578 16467544 (Pubitemid 43209104)
81. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. W Zhang M Gordon AM Schultheis DY Yang F Nagashima M Azuma HM Chang E Borucka G Lurje AE Sherrod S Iqbal S Groshen HJ Lenz, J Clin Oncol 2007 25 3712 3718 17704420 (Pubitemid 47372612)
82. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumours. F Caponigro R Formato M Caraglia N Normanno RV Iaffaioli, Curr Opin Oncol 2005 17 212 217 15818163 (Pubitemid 40586159)
83. Enhancement of antitumour immunity by CTLA-4 blockade. DR Leach MF Krummel JP Allison, Science 1996 271 1734 1736 8596936 (Pubitemid 26102823)
84. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. DM Harper EL Franco C Wheeler DG Ferris D Jenkins A Schuind T Zahaf B Innis P Naud NS De Carvalho CM Roteli-Martins J Teixeira MM Blatter AP Korn W Quint G Dubin GlaxoSmithKline HPV Vaccine Study Group, Lancet 2004 364 1757 15541448
85. A controlled trial of a human papillomavirus type 16 vaccine. LA Koutsky KA Ault CM Wheeler DR Brown E Barr FB Alvarez LM Chiacchierini KU Jansen Proof of Principle Study Investigators, N Engl J Med 2002 347 1645 1651 12444178 (Pubitemid 35340782)
86. Reporting results of cancer treatment. AB Miller B Hoogstraten M Staquet A Winkler, Cancer 1981 47 207 14 7459811
87. New guidelines to evaluate the response to treatment in solid tumours. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther, J Natl Cancer Inst 2000 92 205 16 10655437
88. Cancer immunotherapy: moving beyond current vaccines. S Rosenberg JC Yang NP Restifo, Nat Med 2004 10 909 15 15340416
89. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. D Nagorsen E Thiel, Clin Cancer Res 2006 12 3064 9 16707603
90. Cancer vaccines: pessimism in check. S Mocellin S Mandruzzato V Bronte FM Marincola, Nat Med 2004 10 1278 80 15580242
91. Toll-like receptors. K Takeda T Kaisho S Akira, Annu Rev Immunol 2003 21 335 376 12524386 (Pubitemid 37174535)
92. Costimulation-based immunotherapy for head and neck cancer. SE Strome L Chen, Curr Treat Options Oncol 2004 5 27 33 14697154 (Pubitemid 38906622)
93. Overcoming obstacles to the effective immunotherapy of human cancer. SA Rosenberg, Proc Natl Acad Sci USA 2008 105 12643 4 Epub 2008 Aug; 27. 18753635
94. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. M Lappin J Weiss V Delattre B Mai H Dittmar C Maier K Manke S Grabbe S Martin JC Simon, Immunology 1999 98 181 188 10540216 (Pubitemid 29487638)
95. Induction of an antigen cascade by diversified subcutaneous/intratumoural vaccination is associated with antitumour responses. C Kudo-Saito J Schlom J Hodge, Clin Cancer Res 2005 11 2416 2426 15788693 (Pubitemid 40490203)
96. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. S Tagawa P Lee J Snively W Boswell S Ounpraseuth S Lee B Hickingbottom J Smith D Johnson JS Weber, Cancer 2003 98 144 154 12833467 (Pubitemid 36741137)
97. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. I Bedrosian R Mick S Xu H Nisenbaum M Faries P Zhang PA Cohen G Koski BJ Czerniecki, J Clin Oncol 2003 21 3826 3835 14551301 (Pubitemid 46606238)
98. IL-2 increases the antibody response in patients receiving autologous intralymphatic tumour cell vaccine immunotherapy. T Williams J Ynagimoto A Mazumder C Wiseman, Mol Biother 1992 4 66 69 1515096